This content is from: China (PRC)

China’s patent law draft positive for pharma and patentees

In-house counsel from 3M, State Power Investment and a pharma company support the changes but want to see more implementation clarity

To access our in-house intelligence please request a trial here.

Read this article – and more – for a 30 day period.


Are you already an Managing IP subscriber? Login here


Instant access to all of our content. Membership Options | 30 Day Trial